Items where authors include "Green, C.A."

Article

Abani, O., Abbas, A., Abbas, F. et al. (8041 more authors) (2025) Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Infectious Diseases. ISSN 1473-3099

Chen, J.-L., Wang, B. orcid.org/0000-0002-3746-0188, Lu, Y. orcid.org/0000-0003-4701-5560 et al. (127 more authors) (2025) T cell memory response to MPXV infection exhibits greater effector function and migratory potential compared to MVA-BN vaccination. Nature Communications, 16. 4362. ISSN 2041-1723

Abani, O., Abbas, A., Abbas, F. et al. (8021 more authors) (2025) Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. eClinicalMedicine, 81. 103080. ISSN 2589-5370

Abani, O., Abbas, A., Abbas, F. et al. (8021 more authors) (2025) Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. EClinicalMedicine, 81. 103080. ISSN 2589-5370

Sidhu, J.K., Siggins, M.K. orcid.org/0000-0003-2504-6518, Liew, F. orcid.org/0000-0002-8736-9198 et al. (400 more authors) (2024) Delayed mucosal antiviral responses despite robust peripheral inflammation in fatal COVID-19. The Journal of Infectious Diseases, 230 (1). e17-e29. ISSN 0022-1899

Liew, F., Efstathiou, C. orcid.org/0000-0001-6125-8126, Fontanella, S. et al. (1457 more authors) (2024) Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease. Nature Immunology, 25 (4). pp. 607-621. ISSN 1529-2908

Sandercock, P., Darbyshire, J., DeMets, D. et al. (2050 more authors) (2024) Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Nature Communications, 15. 924. ISSN 2041-1723

Michael, B.D. orcid.org/0000-0002-8693-8926, Dunai, C. orcid.org/0000-0001-5799-2387, Needham, E.J. orcid.org/0000-0001-7042-7462 et al. (559 more authors) (2023) Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses. Nature Communications, 14 (1). 8487. ISSN 2041-1723

Abani, O., Abbas, A., Abbas, F. et al. (7989 more authors) (2023) Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Diabetes & Endocrinology, 11 (12). pp. 905-914. ISSN 2213-8587

Goldswain, H., Dong, X., Penrice-Randal, R. et al. (405 more authors) (2023) The P323L substitution in the SARS-CoV-2 polymerase (NSP12) confers a selective advantage during infection. Genome Biology, 24 (1). 47. ISSN 1474-7596

Roper, K.J., Thomas, J., Albalawi, W. et al. (111 more authors) (2023) Quantifying neutralising antibody responses against SARS-CoV-2 in dried blood spots (DBS) and paired sera. Scientific Reports, 13. 15014. ISSN 2045-2322

Shaw, R.H., Greenland, M., Stuart, A.S.V. et al. (37 more authors) (2023) Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study – a single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines. Journal of Infection, 86 (6). pp. 574-583. ISSN 0163-4453

Abani, O., Abbas, A., Abbas, F. et al. (8104 more authors) (2023) Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet, 401 (10387). pp. 1499-1507. ISSN 0140-6736

Liew, F. orcid.org/0000-0002-8736-9198, Talwar, S., Cross, A. et al. (1439 more authors) (2023) SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination. eBioMedicine, 87. 104402. ISSN 2352-3964

Mentzer, A.J. orcid.org/0000-0002-4502-2209, O’Connor, D. orcid.org/0000-0002-6902-9886, Bibi, S. et al. (66 more authors) (2023) Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection. Nature Medicine, 29 (1). pp. 147-157. ISSN 1078-8956

Shaw, R.H., Liu, X., Stuart, A.S.V. et al. (81 more authors) (2022) Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial. The Lancet Respiratory Medicine, 10 (11). pp. 1049-1060. ISSN 2213-2600

Millar, J.E., Neyton, L., Seth, S. et al. (263 more authors) (2022) Distinct clinical symptom patterns in patients hospitalised with COVID-19 in an analysis of 59,011 patients in the ISARIC-4C study. Scientific Reports, 12. 6843. ISSN 2045-2322

Stuart, A.S.V., Shaw, R.H., Liu, X. et al. (40 more authors) (2022) Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. The Lancet, 399 (10319). pp. 36-49. ISSN 0140-6736

Green, C.A., Kamble, N.S., Court, E.K. et al. (6 more authors) (2019) Engineering the flagellar type III secretion system: improving capacity for secretion of recombinant protein. Microbial Cell Factories, 18. 10. ISSN 1475-2859

Darton, T.C. orcid.org/0000-0003-2209-9956, Jones, C., Blohmke, C.J. et al. (20 more authors) (2016) Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21a. PLoS Negl Trop Dis, 10 (8). e0004926. ISSN 1935-2727